A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of the...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JMIR Publications
2020-07-01
|
Series: | JMIR mHealth and uHealth |
Online Access: | https://mhealth.jmir.org/2020/7/e15448 |
id |
doaj-4d31eff614bb4bd7b7015cbb041d45ef |
---|---|
record_format |
Article |
spelling |
doaj-4d31eff614bb4bd7b7015cbb041d45ef2021-05-03T04:33:24ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222020-07-0187e1544810.2196/15448A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled TrialStaite, EmilyBayley, AdamAl-Ozairi, EbaaStewart, KurtisHopkins, DavidRundle, JenniferBasudev, NeelMohamedali, ZahraIsmail, Khalida BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited. ObjectiveThis randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes. MethodsWe employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A1c (HbA1c) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA1c level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels. ResultsWe enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months. ConclusionsThis study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP. Trial RegistrationClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397https://mhealth.jmir.org/2020/7/e15448 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Staite, Emily Bayley, Adam Al-Ozairi, Ebaa Stewart, Kurtis Hopkins, David Rundle, Jennifer Basudev, Neel Mohamedali, Zahra Ismail, Khalida |
spellingShingle |
Staite, Emily Bayley, Adam Al-Ozairi, Ebaa Stewart, Kurtis Hopkins, David Rundle, Jennifer Basudev, Neel Mohamedali, Zahra Ismail, Khalida A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial JMIR mHealth and uHealth |
author_facet |
Staite, Emily Bayley, Adam Al-Ozairi, Ebaa Stewart, Kurtis Hopkins, David Rundle, Jennifer Basudev, Neel Mohamedali, Zahra Ismail, Khalida |
author_sort |
Staite, Emily |
title |
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial |
title_short |
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial |
title_full |
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial |
title_fullStr |
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial |
title_full_unstemmed |
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial |
title_sort |
wearable technology delivering a web-based diabetes prevention program to people at high risk of type 2 diabetes: randomized controlled trial |
publisher |
JMIR Publications |
series |
JMIR mHealth and uHealth |
issn |
2291-5222 |
publishDate |
2020-07-01 |
description |
BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited.
ObjectiveThis randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes.
MethodsWe employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A1c (HbA1c) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA1c level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels.
ResultsWe enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months.
ConclusionsThis study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP.
Trial RegistrationClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397 |
url |
https://mhealth.jmir.org/2020/7/e15448 |
work_keys_str_mv |
AT staiteemily awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT bayleyadam awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT alozairiebaa awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT stewartkurtis awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT hopkinsdavid awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT rundlejennifer awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT basudevneel awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT mohamedalizahra awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT ismailkhalida awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT staiteemily wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT bayleyadam wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT alozairiebaa wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT stewartkurtis wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT hopkinsdavid wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT rundlejennifer wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT basudevneel wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT mohamedalizahra wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial AT ismailkhalida wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial |
_version_ |
1721484097665105920 |